Reduction of draining tunnels sustained to three years: Of patients who had at least one draining tunnel at baseline, 48.2% had none at one year, and 62.9% at three years* – indicating sustained ...

Over half of patients had no draining tunnels (DTs) at two years: In 425 hidradenitis suppurativa (HS) patients with ≥1 DTs at baseline, 55.7% (195/350) had no DTs at two years of treatment. ≠ DTs are ...

Jeff Stark, MD, vice president and head of immunology, UCB, discusses findings on improved pain management in patients with moderate to severe hidradenitis suppurativa (HS). Treatment with bimekizumab ...

ATLANTA, March 8, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced 48-week post-hoc analyses of pooled Phase 3 data from the BE HEARD I and BE HEARD II studies examining ...

A wave of recently approved therapies has improved options for the control of hidradenitis suppurativa, but surgery remains a possible option for faster clinical benefit.

IFX-1 treatment in high dose group resulted in multiple efficacy signals supporting further development of IFX-1 in HSIFX-1 suppressed C5a levels dose dependently and exhibited a favorable safety ...

Adalimumab in conjunction with surgery demonstrated more clinical effectiveness and improved quality of life in patients with hidradenitis suppurativa (HS) compared with outcomes in those treated with ...

Learning to manage hidradenitis suppurativa can be an ongoing process. The chronic skin condition causes painful lumps under the skin, especially in the armpits, groin, and under the breasts, ...

Hidradenitis suppurativa (HS) is a chronic, painful, and debilitating inflammatory skin disease that is associated with systemic manifestations.2 5,26 The main symptoms are nodules, abscesses, and pus ...